Tumor immunity: A brief overview of tumor‑infiltrating immune cells and research advances into tumor‑infiltrating lymphocytes in gynecological malignancies (Review)
- PMID: 38476909
- PMCID: PMC10928974
- DOI: 10.3892/etm.2024.12453
Tumor immunity: A brief overview of tumor‑infiltrating immune cells and research advances into tumor‑infiltrating lymphocytes in gynecological malignancies (Review)
Abstract
Tumor immunity is a promising topic in the area of cancer therapy. The 'soil' function of the tumor microenvironment (TME) for tumor growth has attracted wide attention from scientists. Tumor-infiltrating immune cells in the TME, especially the tumor-infiltrating lymphocytes (TILs), serve a key role in cancer. Firstly, relevant literature was searched in the PubMed and Web of Science databases with the following key words: 'Tumor microenvironment'; 'TME'; 'tumor-infiltrating immunity cells'; 'gynecologic malignancies'; 'the adoptive cell therapy (ACT) of TILs'; and 'TIL-ACT' (https://pubmed.ncbi.nlm.nih.gov/). According to the title and abstract of the articles, relevant items were screened out in the preliminary screening. The most relevant selected items were of two types: All kinds of tumor-infiltrating immune cells; and advanced research on TILs in gynecological malignancies. The results showed that the subsets of TILs were various and complex, while each subpopulation influenced each other and their effects on tumor prognosis were diverse. Moreover, the related research and clinical trials on TILs were mostly concentrated in melanoma and breast cancer, but relatively few focused on gynecological tumors. In conclusion, the present review summarized the biological classification of TILs and the mechanisms of their involvement in the regulation of the immune microenvironment, and subsequently analyzed the development of tumor immunotherapy for TILs. Collectively, the present review provides ideas for the current treatment dilemma of gynecological tumor immune checkpoints, such as adverse reactions, safety, personal specificity and efficacy.
Keywords: TIL-ACT; TILs; TME; gynecological malignancies.
Copyright: © 2024 Wang et al.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.Expert Opin Biol Ther. 2022 May;22(5):627-641. doi: 10.1080/14712598.2022.2064711. Epub 2022 Apr 20. Expert Opin Biol Ther. 2022. PMID: 35414331 Review.
-
The Role of the Tumor Microenvironment (TME) in Advancing Cancer Therapies: Immune System Interactions, Tumor-Infiltrating Lymphocytes (TILs), and the Role of Exosomes and Inflammasomes.Int J Mol Sci. 2025 Mar 18;26(6):2716. doi: 10.3390/ijms26062716. Int J Mol Sci. 2025. PMID: 40141358 Free PMC article. Review.
-
Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis.Immunol Res. 2023 Aug;71(4):588-599. doi: 10.1007/s12026-023-09376-2. Epub 2023 Apr 1. Immunol Res. 2023. PMID: 37004645 Review.
-
Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?Front Immunol. 2022 Oct 28;13:1018962. doi: 10.3389/fimmu.2022.1018962. eCollection 2022. Front Immunol. 2022. PMID: 36389779 Free PMC article. Review.
-
Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential.Front Oncol. 2021 Feb 16;10:593848. doi: 10.3389/fonc.2020.593848. eCollection 2020. Front Oncol. 2021. PMID: 33680923 Free PMC article. Review.
Cited by
-
Perioperative nursing interventions based on the enhanced recovery after surgery concept for patients with gynecological malignancies: A retrospective study.Medicine (Baltimore). 2025 Jul 25;104(30):e43290. doi: 10.1097/MD.0000000000043290. Medicine (Baltimore). 2025. PMID: 40725890 Free PMC article.
-
T cell subsets in cervical cancer tumor microenvironment: advances and therapeutic opportunities.Front Immunol. 2025 Jun 5;16:1612032. doi: 10.3389/fimmu.2025.1612032. eCollection 2025. Front Immunol. 2025. PMID: 40539072 Free PMC article. Review.
References
-
- Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933–959. doi: 10.1158/2159-8290.CD-20-1808. - DOI - PubMed
-
- Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 Study. J Clin Oncol. 2019;37:1470–1478. doi: 10.1200/JCO.18.01265. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources